,0
symbol,KOD
price,112.45
beta,0.0
volAvg,305306
mktCap,5038142000
lastDiv,0.0
range,24.41-131.01
changes,-10.18
companyName,Kodiak Sciences Inc
currency,USD
cik,0001468748
isin,US50015M1099
cusip,50015M109
exchange,NasdaqGM
exchangeShortName,NASDAQ
industry,Biotechnology
website,https://kodiak.com/
description,"Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for the treatment of retinal diseases. The company is headquartered in Palo Alto, California and currently employs 34 full-time employees. The firm is focused on developing therapeutics to treat ophthalmic diseases. The Companyâ€™s Antibody Biopolymer Conjugate (ABC) platform focuses on merging the fields of antibody-based and chemistry-based therapies. The firm in addition to its lead product candidate, KSI-301, is a molecule for age-related macular degeneration and diabetic retinopathy. The firm has leveraged its ABC platform to build a pipeline of product candidates in various stages of development including KSI-501, a dual inhibitor ABC for the treatment of neovascular retinal diseases, such as wet AMD and diabetic retinopathy."
ceo,DR. Victor Perlroth
sector,Healthcare
country,US
fullTimeEmployees,41
phone,16502810850
address,2631 Hanover St
city,Palo Alto
state,CALIFORNIA
zip,94304
dcfDiff,
dcf,84.3728
image,https://financialmodelingprep.com/image-stock/KOD.png
ipoDate,2018-10-04
defaultImage,False
